Suppression of map kinases inhibits microglial activation and attenuates neuronal cell death induced by α-synuclein protofibrils

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 897-909

  Wilms, H ^a   Rosenstiel, P ^b   Romero Ramos, M ^c   Arlt, A ^d   Schafer H ^d   Seegert, D ^e   Kahle, P J ^f,g   Odoy, S ^f   Claasen, J H ^b   Holzknecht, C ^b   Brandenburg, L O ^b   Deuschl, G ^d   Schreiber, S ^a   Kirik, D ^c   Lucius, Ralph ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e CONARIS Research Institute AG ^*  (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Microglia; Neuroinflammation; Nf b; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SEMAPIMOD;

ARTICLE; CELL ACTIVATION; CELL DEATH; CELL LOSS; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MICROGLIA; NERVE CELL; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 76349097346     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200405     Document Type: Article

References (40)

1. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005; 62:353-7.
2. Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 2004; 364:722-24.
3. Zimprich A, Muller-Myhsok B, Farrer M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004; 74:11-19.
4. George JM. The synucleins. Genome Biol 2002; 3 Epub.
5. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-8.
6. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-7.
7. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998; 21:249-54.
8. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005; 123:383-96.
9. Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K. Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry. Neurosci Lett 2000; 286:69-73.
10. Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 2001; 184:71-5.
11. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003; 106:518-26.
12. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol 2005; 109:141-50.
13. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005; 193:279-90.
14. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005; 19:533-42.
15. Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, McGee, EG, McGeer PL. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 2008; 29:739-52.
16. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 2007; 29: 1690-701.
17. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003; 23:3095-9.
18. Lucius R, Sievers J, Mentlein R. Enkephalin metabolism by microglial aminopeptidase N (CD13). J Neurochem 1995; 64:1841-7.
19. Kahle PJ, Neumann M, Ozmen L, et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001; 159:2215-25.
20. Volles MJ, Lee SJ, Rochet JC, et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001; 40:7812-19.
21. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-9.
22. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003; 17:500-2.
23. Paxinos G, Watson CR, Emson PC. AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 1980; 3:129-49.
24. Hagg T, Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci USA 1993; 90:6315-19.
25. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122:7-14.
26. Lowenberg M, Verhaar A, van den Blink B, ten Kate F, van Deventer S, Peppelenbosch M, Hommes D. Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol 2005; 175:2293-300.
27. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28:7687-98.
28. Sung JY, Park SM, Lee CH, et al. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem 2005; 280:25216-24.
29. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003; 17:1945-47.
30. Lee SJ. Origins and effects of extracellular α-synuclein: implications in Parkinson's disease. J Mol Neurosci 2008; 34:17-22.
31. Zecca L, Wilms H, Geick S, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol 2008; 116:47-55.
32. Zhang W, Dallas S, Zhang D, et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007; 55: 1178-88.
33. Rosenstiel P, Lucius R, Deuschl G, Sievers J, Wilms H. From theory to therapy: implications from an in vitro model of ramified microglia. Microsc Res Tech 2001; 54:18-25.
34. Lorton D, Schaller J, Lala A, De Nardin E. Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease. Neurobiol Aging 2000; 21:463-73.
35. Le Y, Gong W, Tiffany HL, et al. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 2001; 21:RC123.
36. Le Y, Yazawa H, Gong W, Yu Z, Ferrans VJ, Murphy PM, Wang JM. The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J Immunol 2001; 166:1448
37. Brandenburg LO, Koch T, Sievers J, Lucius R. Internalization of PrP106-126 by the formyl-peptide-receptor-like-1 in glial cells. J Neurochem 2007; 101:718-28.
38. Wright JA, Wang X, Brown DR. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J 2009; 23:2384-93.
39. Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic Neurons. PLoS ONE 2008; 3: e1376. doi:10.1371/journal.pone.0001376
40. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119:182-92.